Beta Bionics Q2 EPS Forecast Lifted by Leerink Partnrs

Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) - Equities researchers at Leerink Partnrs increased their Q2 2025 earnings estimates for shares of Beta Bionics in a research report issued on Tuesday, May 6th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of ($0.46) per share for the quarter, up from their previous estimate of ($0.50). Leerink Partnrs currently has a "Strong-Buy" rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics' Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.65) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($1.35) EPS and FY2029 earnings at ($0.88) EPS.

A number of other research firms also recently weighed in on BBNX. Bank of America began coverage on Beta Bionics in a report on Monday, February 24th. They issued a "buy" rating for the company. Stifel Nicolaus started coverage on shares of Beta Bionics in a research note on Monday, February 24th. They set a "buy" rating and a $25.00 price target on the stock. LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a "neutral" rating and a $20.00 price target on the stock. Robert W. Baird initiated coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They set a "neutral" rating and a $20.00 price objective for the company. Finally, Leerink Partners assumed coverage on shares of Beta Bionics in a report on Monday, February 24th. They set an "outperform" rating and a $28.00 target price on the stock. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Beta Bionics currently has a consensus rating of "Moderate Buy" and an average target price of $24.83.

Beta Bionics Stock Performance

BBNX traded down $0.98 on Friday, reaching $13.20. The company had a trading volume of 175,753 shares, compared to its average volume of 479,099. The firm's fifty day simple moving average is $12.56. Beta Bionics has a fifty-two week low of $8.89 and a fifty-two week high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Hedge Funds Weigh In On Beta Bionics

A number of institutional investors and hedge funds have recently bought and sold shares of BBNX. Deutsche Bank AG acquired a new stake in shares of Beta Bionics in the 1st quarter worth $148,000. Rhumbline Advisers acquired a new stake in Beta Bionics during the first quarter worth about $158,000. Invesco Ltd. purchased a new position in Beta Bionics during the first quarter worth about $202,000. Nuveen LLC purchased a new position in Beta Bionics during the first quarter worth about $209,000. Finally, Bank of New York Mellon Corp acquired a new position in Beta Bionics in the 1st quarter valued at about $316,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.